MARATTO

preprint · Research Square (Research Square)

Exploiting of pipazethate HCL as a plant activator targeting a salicylic acid pathway in rice for blast fungus Pyricularia oryzae resistance

Abstract

<title>Abstract</title> Globally, blast disease in rice is one of the most important challenges limiting affected on rice crop productivity. Systemic acquired resistance (SAR) has been broadly investigated in a variety of plant species for enhancing inner resistance to various phytopathogens. The present study aimed to investigate the potential impact of pipazethate HCL as a substance of SAR against <italic>Pyricularia oryzae</italic> in rice. The obtained results showed that pipazethate HCL has no effectiveness of <italic>P. oryzae</italic> on liner growth with various concentrations <italic>in vitro</italic>. However, it significantly improved the level of resistance to rice blast fungus under greenhouse conditions with low and high concentrations under greenhouse conditions. Furthermore, pipazethate HCL, salicylic acid, and tricyclazole 75% are significantly decreasing the number of spores produced on infected rice lesions. Additionally, pipazethate HCL activates some salicylic acid (SA) signaling pathway indicators such as OsWRKY45 and OsNPR1, but jasmonic acid (JA) pathways such as AOS2, JAMYB, and PBZ1 (OsPR10) are not clear. The results suggested that pipazethate HCL is a salicylic acid analog against blast disease in rice inducing SAR that might be interrelated with the defense pathways of SA.

Research topics

  • Plant-Microbe Interactions and Immunity
  • Plant Parasitism and Resistance
  • Plant Pathogens and Fungal Diseases

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21203/rs.3.rs-4404973/v1

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.